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Abstract
Carrying the apoE e4 allele (E4þ ) is the most important genetic risk for Alzheimer’s disease. Unlike non-carriers (E42 ), E4þ seem not
to be protected against Alzheimer’s disease when consuming fish. We hypothesised that this may be linked to a disturbance in n-3
DHA metabolism in E4þ. The aim of the present study was to evaluate [13C]DHA metabolism over 28 d in E4þ v. E42. A total of forty
participants (twenty-six women and fourteen men) received a single oral dose of 40 mg [13C]DHA, and its metabolism was monitored
in blood and breath over 28 d. Of the participants, six were E4þ and thirty-four were E42. In E4þ, mean plasma [13C]DHA was
31 % lower than that in E42, and cumulative b-oxidation of [13C]DHA was higher than that in E42 1–28 d post-dose (P#0·05).
A genotype £ time interaction was detected for cumulative b-oxidation of [13C]DHA (P#0·01). The whole-body half-life of [13C]DHA
was 77 % lower in E4þ compared with E42 (P#0·01). In E4þ and E42, the percentage dose of [13C]DHA recovered/h as 13CO2 correlated
with [13C]DHA concentration in plasma, but the slope of linear regression was 117 % steeper in E4þ compared with E42 (P#0·05). These
results indicate that DHA metabolism is disturbed in E4þ, and may help explain why there is no association between DHA levels in plasma
and cognition in E4þ. However, whether E4þ disturbs the metabolism of 13C-labelled fatty acids other than DHA cannot be deduced from
the present study.
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Regular consumption of fatty fish rich in n-3 PUFA such as
DHA and EPA protects against CVD risk(1,2) and possibly against
cognitive decline(3–5). Several epidemiological studies have
suggested that higher n-3 PUFA concentrations in plasma or
erythrocytes are associated with a lower risk of ageing-associated
cognitive decline(6–9). However, carriers (E4þ ) of the apoE e4
allele, the most important genetic risk factor for Alzheimer’s
disease(10), seem not to be protected against cognitive decline by
the consumption of fish(11). Furthermore, higher erythrocyte n-3
PUFA are not associated with better cognitive function in E4þ (12).
DHA is a major structural component of brain mem-
branes and is essential in neuronal development and repair,
neurotransmission(13), cell signalling and anti-inflammatory
processes(14,15). Synthesis of EPA and DHA from a-linolenic
acid (ALA) is extremely limited in humans(16), so it is advan-
tageous that preformed EPA and DHA be present in the diet.
The concentration of DHA in plasma usually follows a logarith-
mic distribution with dietary DHA intake(17,18), but E4þ have
a lower plasma response to n-3 PUFA supplementation
compared with non-carriers of E4 (E42 )(19). Indeed, after
receiving 3 g/d of EPA þ DHA for 6 weeks, DHA concentration
in plasma TAG increased by 75 % in E4þ, whereas in E42, the
increase was 240 %(19). Thus, E4þ appear to have altered
DHA metabolism when given an n-3 PUFA supplement.
*Corresponding author: Dr M. Plourde, fax þ1 819 829 7141, email melanie.plourde2@usherbrooke.ca
Abbreviations: ALA, a-linolenic acid; APOE, apoE gene; E4þ, apoE e4 allele carriers; E42, apoE e4 non-carriers.
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There are two principal ways to assess DHA metabolism
in human subjects: by perturbing plasma DHA with a DHA
supplement or using isotopically labelled DHA. An oral dose
of uniformly labelled carbon 13 [13C]DHA(20) is a precise and
sensitive tool to evaluate the distribution of DHA in plasma
and b-oxidation over time. [13C]DHA metabolism in human
subjects was first reported more than a decade ago(21–23).
In one study, the authors gave a single oral dose between 250
and 280 mg [13C]DHA in the form of a TAG to three healthy
men(22). [13C]DHA levels reached a maximum 2 h post-dose
in plasma TAG and the apparent retroconversion of [13C]DHA
to [13C]EPA was estimated at 1·4 % of the total plasma con-
centration of [13C]DHA. Recently, we gave 50 mg [13C]DHA
in the form of a methyl ester to six young and six elderly
participants(24) and showed that 4 h after the [13C]DHA intake,
the elderly had a fourfold higher [13C]DHA concentration
in plasma total lipids compared with the young participants(24).
Using [13C]DHA, the objective of the present study was to
evaluate whether DHA metabolism is different in E4þ v.
E42. We report the distribution of [13C]DHA in plasma total
lipids, its apparent retroconversion to EPA detected in
plasma total lipids, the b-oxidation of [13C]DHA recovered
in breath in the form of 13CO2, and plasma and the whole-
body half-life of [13C]DHA.
Methods
A total of forty participants over 50 years of age were recruited
between January 2010 and April 2011 in the Eastern Town-
ships of Quebec, Canada. All participants completed the
thirty-item Montreal Cognitive Assessment test for baseline
cognitive status(25). Participants were all non-smokers, and
free of dementia or diabetes. They did not have a diagnosis
of cancer in the past 6 months, liver or renal disease, uncon-
trolled hyper- or hypothyroidism, autoimmune disorder,
elevated markers of inflammation or low serum albumin.
Anyone consuming n-3 PUFA capsules was excluded. The
present study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
involving human participants were approved by the Human
Ethics Research Committee of the Health and Social Sciences
Center – Sherbrooke University Geriatrics Institute, which is
the committee mandated to oversee human experimentation
at our institution. Written informed consent was obtained
from all participants. The study is registered at www.clinical-
trials.gov (NCT01577004).
Tracer study design
The [13C]DHA used in the present study was uniformly
labelled (.98 %) and of high chemical purity (99 % pure).
It was synthesised using micro-algae fed with [13C]glucose.
Each 40 mg dose of [13C]DHA methyl ester was stored in an
individual glass ampoule sealed under Ar(20).
Participants arrived fasted on the morning of the metabolic
study day. After collecting baseline blood and breath samples
(see details below), the participants received a breakfast
composed of two pieces of whole-wheat grain toast with
peanut butter, one scrambled egg, one apple, 35 g mozzarella
cheese and 250 ml orange juice. The macronutrient compo-
sition of this 2805 kJ breakfast was as follows: 25·5 g fat, 78 g
carbohydrate and 29 g protein. The 40 mg dose of [13C]DHA
was added to a piece of toast. The breakfast was consumed
by all participants within 15 min. At 4 h after tracer consump-
tion, the participants were given a lunch composed of
lasagne with 200 ml of V8 vegetable juice and a granola bar.
The macronutrient composition of this 2093 kJ lunch was as
follows: 15 g fat, 88 g carbohydrate and 23 g protein.
[13C]DHA metabolism was monitored in blood and breath
samples collected at baseline (0 h) and at 1, 2, 4, 6 and 8 h
post-dose. The participants returned to the metabolic unit 1,
7, 14, 21 and 28 d post-dose for blood and breath sample
collection. A 28 d follow-up was used since this is the typical
amount of time needed for [13C]DHA in plasma to return
to baseline(24). A catheter was installed in a forearm vein
for the collection of blood samples on the first day; later,
blood samples were collected using a 5 ml syringe (Becton
Dickinson) and transferred into 4 ml EDTA tubes (Becton
Dickinson). The tubes were centrifuged at 2300 g for 15 min
at 48C, and plasma was stored in three 0·5 ml Eppendorfs at
2808C until further analyses.
To assess the appearance of 13CO2 coming from the
b-oxidation of [13C]DHA, participants breathed into a device
consisting of a perforated plastic bag attached to a mouthpiece
(EasySampler; QuinTron Instrument Company) to which an
evacuated glass tube was inserted to collect a sample of the
exhaled breath(26,27).
Analytical methods
Total lipids were extracted from 0·25 ml of plasma using the
method described by Folch et al.(28). Heptadecanoate was
added as an internal standard for quantification of fatty
acids. To remove cholesterol, the total lipid extract was then
saponified using 3 ml of 1 M-KOH–methanol and the mixture
was heated at 908C for 1 h. Transmethylation of the resulting
NEFA into fatty acid methyl esters was performed using
14 % boron trifluoride–methanol (Sigma-Aldrich). Fatty acid
methyl esters were analysed using a gas chromatograph
(model 6890; Agilent) equipped with a 50 m BPX-70 fused
capillary column (SGE). Injection and flame ionisation detec-
tion were performed at 2508C with the following oven tem-
perature programme: 508C for 2 min, increased by 208C/min
to 1708C for 15 min and finally increased by 58C/min to
2108C for 7 min. He gas was used as a carrier and the inlet
pressure was 233 kPa at 508C. The identity of individual fatty
acids was determined using standard mixtures of fatty acids
(NuChek 68A, NuChek 411 and NuChek 455; NuChek Prep,
Inc.) and a custom mixture of SFA.
[13C]DHA enrichment analysis in plasma total lipids was per-
formed using GC–combustion–isotope ratio MS, as described
previously(29). 13C/12C post-dose was compared with baseline
13C/12C (pre-dose) to calculate the d (per mil) values that were
designated thereafter as atom per cent excess. Calculations of
[13C]DHA (nmol/ml) and [13C]EPA (pmol/ml) from the atom
R. Chouinard-Watkins et al.1752
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per cent excess values were performed according to Brossard
et al.(22).
Enrichment of 13C in breath CO2 after [
13C]DHA consump-
tion was analysed by isotope ratio MS (ABCA, Sercon Limited),
as described previously(27). He gas (Praxair) was used as a
carrier and 5 % CO2/N2 as the reference gas. The percentage
dose of [13C]DHA recovered in breath as 13CO2 was calculated
as described previously(26), except that basal metabolism was
evaluated using indirect calorimetry (CCM/D; Medgraphics
Corporation) to measure the volume of CO2 and O2 exhaled
by the participants over 30 min(30). Cumulative b-oxidation
of [13C]DHA was calculated from the AUC of the percentage
dose recovered at each time point (GraphPad Prism 5 soft-
ware; GraphPad Software, Inc.).
[13C]DHA half-life in plasma was calculated using RxKinetics
online software (RxKinetics; www.rxkinetics.com). The values
of two E42 participants were excluded because [13C]DHA
concentrations in plasma were not available for time points
14, 21 and 28 d. [13C]DHA half-life in the whole body was esti-
mated for each participant using cumulative 13CO2 data. For
three E4þ and twenty-five E42 not reaching a cumulative
b-oxidation of 50 % 28 d post-dose, it was assumed from the
cumulative 13CO2 data of the other participants that beyond
28 d, the curve would be linear (see Fig. 1(d)). Therefore,
using the cumulative 13CO2 data at times 1, 7, 14, 21 and
28 d post-dose, a linear equation in the form of y ¼ mx þ b,
where m is the slope and b is the y value when x ¼ 0, was
calculated for each participant to estimate the time needed
(x) to reach 50 % (y) of cumulative b-oxidation of [13C]DHA
recovered as 13CO2. As a result, five E42 were excluded
because b-oxidation of [13C]DHA recovered as 13CO2 reached
a plateau of ,50 % 7 d post-dose, so it was not possible to
estimate the whole-body [13C]DHA half-life. Correlations
between [13C]DHA concentration in plasma and the percen-
tage dose of [13C]DHA recovered as breath 13CO2 were per-
formed using all time points for all participants (n 58 for
E4þ and n 314 for E42 ). Baseline values of 13C in plasma
DHA and the percentage of 13C in CO2 were removed
before the correlations between [13C]DHA concentration in
plasma and the percentage dose of [13C]DHA recovered as
breath 13CO2 since these values were standardised at zero in
our calculations. The slopes of the linear regression between
[13C]DHA concentration in plasma and the percentage dose
of [13C]DHA recovered as breath 13CO2 was calculated and
compared between E4þ and E42 .
ApoE genotyping
DNA of the participants was extracted from 200ml of whole
blood (QIAmp DNA Blood Mini Kit; Qiagen). The DNA frag-
ment containing the apoE gene (APOE) sequence was amplified
by PCR (Perkin Elmer GeneAmp PCR System 2400; Perkin Elmer)
using the oligonucleotide primers F6 (50-TAAGCTTGGCACGGC-
TGTCCAAGGA-30) and F4 (50-ACAGAATTCGCCCCGGCCTGGT-
ACAC-30), as described previously(31). After amplification, the
DNA fragment was digested using Hha I (New England Biolabs
Ltd) in order to reveal differential digestion patterns related to
the APOE genotype. DNA fragments were then loaded on
a 20 % polyacrylamide gel for migration at 220 V for 3 h and
the fragments were revealed using ethidium bromide(32).
2·4
3·0
0
5
10
15
20
25
2·5
2·0
1·5
1·0
0·5
0
2·0
1·6
1·2
0·8
0·4
0·0
[1
3 C
]D
H
A
(n
m
o
l/m
l p
la
sm
a)
[1
3 C
]D
H
A
(p
m
o
l/m
l p
la
sm
a)
0·4
0·3
0·2
0·1
0·0
01 2 4 6 8 1 7 14 21 28
DaysHours
(a) (b)
(c) (d)
01 2 4 6 8 1 7 14 21 28
DaysHours
01 2 4 6 8 1 7 14 21 28
DaysHours
01 2 4 6 8 1 7 14 21 28
DaysHours
100
80
60
40
20
0
13
C
O
2 
(%
 d
o
se
/h
)
13
C
O
2
(c
u
m
u
la
ti
ve
 %
 d
o
se
)
Fig. 1. [13C]DHA metabolism over 28 d after an oral dose of 40 mg [13C]DHA in apoE e4 carriers (E4þ , D, n 6) and non-carriers (E42 , B, n 34). (a) [13C]DHA
concentration (nmol/ml) in plasma total lipids, (b) [13C]DHA apparent retroconversion into [13C]EPA in plasma total lipids, (c) the percentage dose of [13C]DHA
recovered/h as 13CO2 in breath and (d) the cumulative percentage dose of [
13C]DHA recovered as 13CO2 over 28 d of follow-up. In (d), the left curves
follow the left y-axis, whereas the right curves follow the right y-axis. The estimated slope of the right curve (m) was 0·09 (SEM 0·03) in E4þ v. 0·05 (SEM 0·01)
in E42 (P¼0·03). Values are means, with their standard errors represented by vertical bars. There were significant effects for (a) genotype (P¼0·04) and (d) the
genotype £ time interaction (P¼0·003).
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Data expression and statistics
Sample size was based on a calculation that the maximum
concentration of [13C]DHA in plasma total lipids that
would be reached in the postprandial period would be
0·9 nmol/ml(24). From our previous study(24), we estimated
that a twofold difference in plasma [13C]DHA concentration
would be observed between E4þ and E42 in the postpran-
dial period(19). Therefore, the sample size required to detect
this difference using a 5 % significance level and a power of
80 % was six subjects per group(33). We based our sample
size calculation only on plasma [13C]DHA concentration
because DHA in plasma is one of the best documented
biomarkers of the difference between E4þ and E42 (19).
Moreover, since pre-screening for E4þ is not permitted at
our institution, we therefore enrolled forty participants to
recruit at least six E4þ on the assumption that E4þ frequency
is approximately 15–25 %(34,35) in the general population,
heterozygous and homozygous E4þ combined. Data are
shown as means with their standard errors.
Statistics in Fig. 1 were performed using the PROC MIXED
procedure implemented in SAS since some participants had
missing data (SAS 9.2; SAS Institute)(36). This procedure was
used instead of a classical two-way ANOVA to optimise the
use of all data over time and maintain statistical power. The
PROC MIXED procedure allows testing for the effect of time
as a repeated measure, genotype as a fixed factor (E4þ v.
E42 ) and the interaction genotype £ time. Student’s t tests
were performed on Fig. 2, Table 1 and Table 2 to detect sig-
nificant differences between E4þ and E42 (SPSS 17.0;
SPSS, Inc.). The correlation coefficient (R) of the correlations
between plasma [13C]DHA and [13C]DHA recovered/h as
breath 13CO2 was performed using the bivariate correlation
program in SPSS (Fig. 3). To account for potential confound-
ing factors, correlation analyses were performed between
[13C]DHA recovered/h as breath 13CO2 and baseline character-
istics such as age, sex, cholesterol levels, glucose levels and
medications. Statistically significant correlations were included
in a multiple linear regression model. The slopes (b) of the
linear regression between plasma [13C]DHA and [13C]DHA
recovered/h as 13CO2 were compared between E4þ and
E42. For cumulative b-oxidation of [13C]DHA recovered as
13CO2 between E4þ and E42, a simple linear regression
model was used to compare the slope (m) between 1 d and
28 d post-dose. Statistical significance was set at P#0·05.
Results
In the present study, six participants were E4þ (five E3/E4
and one E2/E4, two men and four women) and thirty-
four were E42 (twenty-eight E3/E3 and six E2/E3, twelve
men and twenty-two women). In E4þ, the mean age was
68·0 (SEM 3·3) years, whereas it was 72·4 (SEM 1·5) years in
E42 (NS; Table 1). There was no difference in baseline
characteristics between E4þ and E42 (Table 1) and between
men and women (data not shown). The participants’ score on
the thirty-item Montreal Cognitive Assessment test was 26·1
(SEM 0·5) (maximum score of 30), indicating that they were
cognitively healthy at baseline(25). In E4þ at baseline, the
mean plasma DHA concentration was 73 (SEM 9) mg/l, which
was equivalent to 1·9 (SEM 0·4) % of plasma total fatty acids,
whereas in E42, DHA concentration was 60 (SEM 4) mg/l,
which was equivalent to 1·6 (SEM 0·1) % of plasma total fatty
acids (Table 2). There was no difference in fasting plasma
fatty acid compositions between E4þ and E42 (Table 2).
[13C]DHA metabolism in apoE e4 allele carriers v. apoE
e4 non-carriers
The PROC MIXED procedure detected no genotype £ time
interaction with plasma [13C]DHA (Fig. 1(a)). Nevertheless, a
genotype effect was detected for plasma [13C]DHA, such that
in E4þ, [13C]DHA in plasma total lipids from 1 h to 28 d
post-dose was 31 % lower compared with E42 (mean 0·66
(SEM 0·14) nmol/ml in E4þ v. 0·96 (SEM 0·11) nmol/ml in
E42, P¼0·04; Fig. 1(a)). In both groups, [13C]DHA peaked in
plasma total lipids 6 h after tracer intake; in E4þ, the maximum
value of [13C]DHA was 1·5 (SEM 0·3) nmol/ml, whereas it was
2·0 (SEM 0·2) nmol/ml in E42 (NS; Fig. 1(a)).
The apparent retroconversion of [13C]DHA into [13C]EPA
peaked 1 d post-dose, but was not different between E4þ
and E42 and no genotype £ time interaction was detected
for plasma [13C]EPA concentration (Fig. 1(b)). In E4þ,
[13C]EPA concentration in plasma total lipids reached a maxi-
mum of 17·4 (SEM 3·1) pmol/ml, representing 1·2 % of the
peak plasma [13C]DHA concentration, whereas in E42,
[13C]EPA concentration in plasma total lipids reached a maxi-
mum of 14·4 (SEM 2·4) pmol/ml, representing 0·7 % of the
peak [13C]DHA concentration (NS; Fig. 1(b)).
The percentage dose of [13C]DHA recovered/h as 13CO2 did
not differ at any time point between E4þ and E42 over
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the 28 d of the study (Fig. 1(c)). On the other hand, a
genotype £ time interaction was detected with regard to
cumulative b-oxidation of [13C]DHA recovered as 13CO2
(P¼0·003; Fig. 1(d)). Moreover, in E4þ, the slope of the cumu-
lative 13CO2 line (m) between 1 and 28 d post-dose was 80 %
steeper than in E42 (m ¼ 0·09 (SEM 0·03) in E4þ v. m ¼ 0·05
(SEM 0·01) in E42, P¼0·03; Fig. 1(d)). In E4þ, cumulative b-
oxidation of [13C]DHA recovered as 13CO2 reached a maxi-
mum of 68 (SEM 22) % 28 d post-dose, whereas it reached 35
(SEM 7) % in E42 (NS; Fig. 1(d)).
The [13C]DHA half-life in plasma was 4·6 (SEM 0·8) d in E4þ
and 4·5 (SEM 0·4) d in E42 (NS; Fig. 2(a)). The whole-body
[13C]DHA half-life was heterogeneous and was 77 % lower in
E4þ compared with E42 (32 (SEM 8) d in E4þ v. 140 (SEM
28) d in E42, P¼0·001; Fig. 2(b)). In two E4þ, the mean
whole-body [13C]DHA half-life was 53 d, whereas in four
other carriers, it was 21 d (Fig. 2(b)). In eleven E42, the
whole-body [13C]DHA half-life was .200 d, whereas in four-
teen other E42, it was ,50 d and in four E42, it was between
50 and 200 d (Fig. 2(b)).
Correlation between [13C]DHA concentration in plasma
and the percentage dose of [13C]DHA recovered/h as
13CO2
In E4þ and E42, the percentage dose of [13C]DHA recovered/h
as 13CO2 correlated positively with [
13C]DHA concentration in
plasma (R 0·56 in E4þ and R 0·39 in E42, P,0·001 for both;
Fig. 3). The percentage dose of [13C]DHA recovered/h as
13CO2 also correlated with the levels of LDL-cholesterol and
was associated with the use of a statin, so these potential con-
founding factors were included in the multivariate linear
regression model. There was a positive interaction between
genotype and linear regression of the percentage dose of
[13C]DHA recovered/h as 13CO2 (y) with [
13C]DHA concen-
tration in plasma (x), and this interaction remained significant
when accounting for confounding factors (P,0·001; Fig. 3).
The slope of the linear regression (b) was 117 % steeper in
E4þ compared with E42 (b ¼ 0·13 (SEM 0·03) in E4þ v.
b ¼ 0·06 (SEM 0·01) in E42, P,0·001).
Discussion
These results demonstrate that [13C]DHA metabolism is disturbed
in E4þ compared with E42 since E4þ had a 31% lower
mean concentration of [13C]DHA in plasma total lipids over
time, but increased b-oxidation between 1 and 28d post-dose.
This difference may be due, at least in part, to the key role of
Table 1. Baseline characteristics of apoE e4 allele carriers (E4þ) and
apoE e4 non-carriers (E42 )
(Mean values with their standard errors)
E4þ (n 6) E42 (n 34)
Mean SEM Mean SEM P
Age (years) 68·0 3·3 72·4 1·5 0·35
Sex (n)
Male 2 12
Female 4 22
BMI (kg/m2) 29·3 2·3 27·2 0·7 0·57
H1Ac Hb (%) 6·0 0·2 5·8 0·1 0·21
Glucose (mmol/l) 5·1 0·4 4·7 0·1 0·72
TSH (mIU/l) 1·9 0·2 1·9 0·2 0·25
Total cholesterol (mmol/l) 4·9 0·4 4·9 0·1 0·82
HDL-cholesterol (mmol/l) 1·3 0·2 1·4 0·1 0·57
LDL-cholesterol (mmol/l) 2·6 0·5 2·8 0·1 0·42
CRP (mg/l) 3·1 1·6 3·6 0·7 0·40
TAG (mmol/l) 2·2 0·8 1·4 0·1 0·90
MoCA test score* 25·3 1·1 26·2 0·5 0·22
Medications (n)†
Anti-hypertension agents‡ 3 15
Statins 3 14
Acetylsalicylic acid 1 4
Levothyroxine 0 6
Biphosphonate 1 7
TSH, thyroid-stimulating hormone; CRP, C-reactive protein; MoCA, Montreal Cognitive
Assessment.
* Score out of a maximum of 30.
† The number of subjects in each group receiving each medication.
‡ Anti-hypertensive agents include angiotensin-converting enzyme inhibitors, angio-
tensin receptor antagonists, b-blockers, Ca channel blockers and diuretics.
Table 2. Fatty acid concentration (mg/l) and percentage in plasma total lipids of apoE e4 allele carriers (E4þ) (n 6)
and apoE e4 non-carriers (E42 ) (n 34) at baseline
(Mean values with their standard errors)
Concentrations (mg/l) Relative percentage (%)
E4þ E42 E4þ E42
Fatty acids Mean SEM Mean SEM P Mean SEM Mean SEM P
14 : 0 45·0 9·0 41·0 4·0 0·71 1·0 0·2 1·1 0·1 0·72
16 : 0 1025·0 167·0 833·0 38·0 0·31 23·0 1·3 22·5 0·4 0·67
16 : 1n-7 123·0 37·0 95·0 8·0 0·48 2·6 0·5 2·5 0·2 0·89
18: 0 286·0 34·0 246·0 8·0 0·30 6·6 0·3 6·8 0·2 0·62
18 : 1n-9 1130·0 231·0 824·0 41·0 0·25 24·8 2·4 22·2 0·4 0·33
18 : 1n-7 84·0 19·0 61·0 3·0 0·30 1·8 0·2 1·6 0·1 0·44
18 : 2n-6 1113·0 43·0 1081·0 52·0 0·80 27·4 3·2 29·5 0·9 0·54
20 : 3n-6 64·0 11·0 54·0 3·0 0·46 1·4 0·1 1·5 0·1 0·53
20 : 4n-6 282·0 21·0 254·0 13·0 0·40 6·8 0·7 6·9 0·2 0·82
18 : 3n-3 36·0 4·0 34·0 3·0 0·74 0·9 0·1 0·9 0·1 0·75
20 : 5n-3 36·0 6·0 35·0 3·0 0·94 0·9 0·2 1·0 0·1 0·76
22 : 5n-3 20·0 2·0 21·0 1·0 0·77 0·5 0·1 0·6 0·1 0·27
22 : 6n-3 73·0 9·0 60·0 4·0 0·24 1·9 0·4 1·6 0·1 0·59
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apoE in postprandial plasma lipoprotein and lipid metab-
olism(37). ApoE has a high affinity for the LDL receptor that is
involved in lipoprotein clearance from the plasma, notably chy-
lomicron remnants and VLDL(38). E4þ have a lower concen-
tration of apoE protein in plasma(39), but with proportionally
more apoE inVLDL and less inHDL comparedwith homozygous
carriers of apoE e3(40). Therefore, clearance of VLDL in E4þ is
potentially more rapid since this process relies partly on the
binding of apoE protein with the LDL receptor(40). Fatty acids
travel in the blood mostly via lipoproteins, so a more rapid
VLDL turnover potentially enhances [13C]DHA clearance from
the plasma, thereby supporting the present observation of
lower plasma [13C]DHA concentrations in E4þ. Moreover,
[13C]DHA was ingested in the form of a methyl ester. Hence,
it is possible that the observed differences in [13C]DHA con-
centrations between E4þ and E42 might be partly due to a
difference in the cleavage capacity of this form of DHA in E4þ,
although, to our knowledge, no study has evaluated
this question.
Several studies have shown that E4þ have higher plasma
TAG than E42 in the postprandial state(41,42), and that there
is an age £ APOE genotype interaction with regard to TAG
metabolism after an oral fat load(41,43). Postprandially, E4þ
over 50 years old had a higher AUC for plasma TAG concen-
trations compared with E42, whereas this difference was
absent between younger E4þ and E42 (41). In the present
study, all participants were aged .50 years old, so we
would anticipate a higher DHA concentration in the post-
prandial state because of higher postprandial TAG levels in
E4þ. However, there was no difference between E4þ and
E42 in total postprandial DHA expressed either in mg/l
or in relative percentage to other fatty acids. Nevertheless,
TAG levels during the postprandial state were not evaluated
in the present study, so we cannot confirm the results
obtained by Carvalho-Wells et al.(41) with regard to TAG con-
centrations in the postprandial state between E4þ and E42 .
We report here for the first time the b-oxidation of [13C]DHA
in E4þ and E42. E4þ had higher cumulative b-oxidation of
[13C]DHA than E42 between 1 and 28 d post-dose (Fig. 1(d)).
The estimated slope (m) of the cumulative b-oxidation of
[13C]DHA between 1 and 28 d post-dose was 80 % steeper in
E4þ than in E42 (Fig. 1(d)), suggesting a higher rate of
the b-oxidation of [13C]DHA in E4þ compared with E42.
This result could help explain the lower plasma [13C]DHA in
E4þ compared with E42. The cumulative b-oxidation of
[13C]DHA 24 h post-dose was 6 % in E4þ and 5 % in E42
(NS; Fig. 1(d)), which was nearly 75 % lower compared with
other common dietary fatty acids such as oleic acid (29 %),
linoleic acid (21 %) or ALA (31 %)(27). This suggests that in
humans habitually consuming low levels of DHA, DHA is
efficiently conserved, probably because of its structural
importance in cell membranes(44) and as a precursor to
signalling molecules derived from DHA, notably resolvins
and protectins(45).
Plasma [13C]DHA correlated with the percentage dose of
[13C]DHA recovered/h as 13CO2 in both E4þ and E42, but the
slope (b) of this relationship was 117 % steeper in E4þ than
in E42 (P,0·001; Fig. 3). Thus, for a given plasma concen-
tration of [13C]DHA, 13CO2 was higher in E4þ than in E42,
showing more rapid b-oxidation of DHA. This difference in
retention v. oxidation of DHA in E4þ is consistent with our
previous report that the increase in plasma DHA after supple-
menting with EPA þ DHA was lower in E4þ than in E42 (19).
b-Oxidation of DHA is thought to be mainly conducted in per-
oxisomes(46), but the relative contribution of peroxisomal v.
mitochondrial b-oxidation to the whole-body production of
13CO2 from [
13C]DHA in humans is unknown. To the best of
our knowledge, there are currently no available data supporting
a potential role of APOE4 polymorphism on the expression
and/or activity of these peroxisomal enzymes b-oxidising
DHA. A recent review by Lizard et al.(47) has suggested the
potential dysfunction of peroxisomal metabolism in patients
with Alzheimer’s disease. Since E4þ are more at risk to
develop Alzheimer’s disease, the present results showing
more b-oxidation of [13C]DHA needs further investigation
since the APOE genotype may potentially affect Alzheimer’s
disease risk by affecting the molecular mechanism involved in
fatty acid b-oxidation.
The present study is also the first to estimate plasma and
whole-body half-lives of [13C]DHA. In previous studies, calcu-
lation of [13C]DHA half-life was not possible since a follow-up
of ,72 h did not provide enough time for plasma [13C]DHA to
return to baseline(22). In our previous study(24), b-oxidation of
[13C]DHA was monitored over 7 d post-dose and gave a rough
estimate of the [13C]DHA whole-body half-life of about 10 d,
which is 66 % less than our current estimate for E4þ and
90 % less for E42 (Fig. 2). However, in the present study,
b-oxidation of [13C]DHA was followed over 28 d and the
number of participants was higher than previously(22–24),
thus permitting a more accurate estimate of the whole-body
half-life of [13C]DHA. We estimated that the whole-body
half-life of [13C]DHA was approximately 25 d more than
its plasma half-life in E4þ and .100 d more than its
plasma half-life in E42. Moreover, the whole-body half-life
0·8
0·6
0·4
0·2
0·0
13
C
O
2 
(%
 d
o
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/h
)
[13C]DHA (nmol/ml plasma)
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Fig. 3. Linear regression between [13C]DHA concentration (nmol/ml) in
plasma total lipids and the percentage dose of [13C]DHA recovered/h as
13CO2 in the breath of apoE e4 carriers (E4þ , D, , n 58, R 0·56) and
non-carriers (E42 , B, , n 314, R 0·39) over 28 d of follow-up. The
linear regression model had a slope (b) of 0·13 (SEM 0·03) in E4þ v. 0·06
(SEM 0·01) in E42 (P,0·001).
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of [13C]DHA was 77 % lower in E4þ compared with E42,
corroborating higher b-oxidation of [13C]DHA in E4þ. Since
the whole-body half-life values of [13C]DHA were highly
heterogeneous in the E42 group, we investigated potential
factors besides the APOE genotype that could be associated
with a higher or lower whole-body half-life. No association
was found between the whole-body half-life of [13C]DHA
and age, sex, baseline TAG levels, BMI, baseline DHA or
EPA status and medications (data not shown).
The apparent retroconversion of [13C]DHA into [13C]EPA was
1·2 %, which is similar to the level reported previously(22,24).
These results suggest that most of the [13C]DHA remain in its
native form in human subjects, whereas E4þ tend to have
an overall higher b-oxidation of [13C]DHA without producing
more [13C]EPA compared with E42 .
A potential confounding factor worth considering in the pre-
sent study was whether sex disturbed DHA metabolism, as
suggested by other studies(48–52), since the results presented
here involved men and women pooled together. Previous
studies have shown that women tend to have higher DHA and
EPA in plasma total lipids compared with men(48), and this is
potentially because of a higher conversion of ALA to EPA and
DHA in women(49,51,53) compared with men(54). Moreover,
using [13C]ALA, a study has reported higher b-oxidation in
men compared with women, which was associated with
higher 13C enrichment in saturated acids and monounsaturated
acids, suggesting a preferential pathway towards ALA degra-
dation in men(52). These sex-specific differences in n-3 PUFA
metabolism seem to be in part explained by higher estrogens
in pre-menopausal women(50). In the present study, there was
no difference in plasma [13C]DHA, plasma DHA or [13C]DHA
half-lives in the whole body or plasma between men and
women (data not shown). This is probably because our parti-
cipants were approximately 71 years old and all the women
were postmenopausal. The drop in estrogen levels following
menopause(55) probably contributed to the lack of sex-specific
differences in [13C]DHA metabolism in the present study.
The present study had limitations. The number of E4þ was
small when compared with E42, but baseline characteristics
were similar between the two groups (Table 1). Moreover,
sample size calculation indicated that six participants should
be enough to detect a significant difference in [13C]DHA
metabolism. Pre-screening for E4þ is not permitted at our
institution, so the only alternative for recruiting E4þ parti-
cipants is to run the trial and perform APOE genotyping
afterwards. There was no difference in cholesterol levels
between E4þ and E42, even though other studies have
suggested otherwise(56–58), but our participants were
elderly and three E4þ and fourteen E42 were on statins
during the study. No difference in [13C]DHA appearance in
plasma and b-oxidation was observed when comparing the
participants taking statins or not (data not shown). Another
limitation of the present study was that [13C]DHA was the
only fatty acid tracer used to follow precisely its metabolism.
Hence, whether E4þ disturbs the metabolism of fatty acids
other than DHA cannot be deduced from the present study
and will need further work with 13C-labelled fatty acids
other than DHA.
Conclusion
Compared with E42, E4þ had lower mean plasma [13C]DHA
between 1 h and 28 d post-dose, whereas b-oxidation of
[13C]DHA was higher between 1 and 28 d post-dose. For a
similar level of [13C]DHA in plasma, E4þ had higher 13CO2 in
breath and a lower whole-body half-life of [13C]DHA compared
with E42, suggesting higher [13C]DHA catabolism in E4þ.
Nevertheless, plasma [13C]DHA half-life was similar between
E4þ and E42. Therefore, there seems to be no clear relation-
ship between plasma half-life and the kinetics of [13C]DHA
metabolism. Given that DHA is important for cardiovascular
and brain health, disturbance in [13C]DHA metabolism in E4þ
may increase their vulnerability to cognitive decline or other
diseases. These results may help explain why no association
between plasma DHA and cognition has been observed
in E4þ. Further studies evaluating [13C]DHA metabolism after
a DHA supplement are needed to evaluate whether a high
dose of EPA þ DHA could return DHA homeostasis in E4þ
towards normal.
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